Three months ago, antitrust authorities in Italy fined Novartis and Roche $251 million on charges they colluded to protect sales of their eye drug, Lucentis. Now, that country's Health Ministry is seeking further damages.
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top.
After an FDA rejection and an earlier negative opinion, Novartis' cardio treatment serelaxin has again failed to sway European regulators, and the drugmaker has resigned that its breakthrough-designated therapy will not hit any market this year.
Rivals Novartis and Boehringer Ingelheim are touting positive results for their combination COPD treatments, duking it out with GlaxoSmithKline for dominance of a market that could reach $14 billion by 2018.
With all of the pharma layoffs, lots of folks are looking for a job in the industry. So where are the best places to work? Johnson & Johnson and Novartis if you want to work for a large company. Biogen Idec, Gilead or perhaps Novo Nordisk if you prefer more of a midsize drugmaker.
Novartis has scooped up the ex-U.S. rights to Ophthotech's Fovista--its late-stage therapy for wet age-related macular degeneration that hopes to one day rival heavyweight franchises controlled by Roche and Regeneron--in a package deal potentially worth more than $1 billion.
The FDA rejected the heart drug serelaxin, the latest blow to a treatment Novartis hoped would be a cornerstone of a cardiovascular franchise.
India-based HCL Technologies has shown a skill for winning Big Pharma contracts, like the $500 million deal it inked with Merck in 2010. HCL has now added Novartis to its list of clients, with the Swiss pharma signing up to outsource its infrastructure management to the IT services company.
After nearly a year of fighting to protect the patent on its blockbuster leukemia drug Gleevec, Novartis has made peace with Indian drugmaker Sun Pharma, reaching a settlement that will keep Sun's generic version off the U.S. market until February 2016, Reuters reports. Novartis' U.S. patent expires in July 2015.
France's Servier has struck up a deal with Novartis to develop oncology drugs that invade tumors and lead them to self-destruct.